1. Семиглазов В.Ф., Семиглазов В.В., Нургазиев К.Ш. Обоснование стандартов лечения рака молочной железы. М., 2007; с. 202–3.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; V365: 1687–717.
3. EBCTCG New advances in the treatment of breast cancer. San Antonio, 2007.
4. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319–29.
5. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
6. Zilembo N, Bajetta E, Martinetti A et al. Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA). Eur J Cancer 2001; 37(Suppl. 6): S193.
7. Gossa PE, Qia S, Josseb RG et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34 (3): 384–92.
8. Lohrisch C, Paridaens R, Dirix L et al. No adverse impact on serum lipids of the irreversible aromatase inactivator AromasinR (Exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization for the Research and Treatment of Cancer (Breast Group) Trial with Pharmacias' Upjohn. Proc Am Soc Clin Oncol 2001; 20 (43a): Abstr. 167.
9. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399–411.
10. Paridaens RJ, Dirix LY, Beex LV et al. Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26 (30): 4883–90.
11. Coombes RS, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen therapy after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559–70.
12. Coombes RS, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
13. Bliss JM, Kilburn LS, Coleman RE et al. Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES). Cancer Res 2009; 69 (Suppl.): 487s, abstr. 12.
14. Mamounas E, Jeong J-H, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S22 (Abstr 49).
15. Saphner T, Tormey DC, Grayet R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738–46.
16. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.
17. Dowsett M, Allred C, Knox J et al. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008; 26 (7): 1059–65.
18. Goldhirsch A., Wood WS, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44.
19. Van de Velde C, Seynaeve C, Hasenburg A et al. Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. EJC 2009; 7, 3 (Suppl.): p 1, abstr. 2BA.
20. Jones SE, Seynaeve C, Hasenburg A et al. Results of the first analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. SABS 2008.
21. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in randomized, cross-over study. J Clin Oncol 2002; 20: 751–7.
22. Geisler J, King N B, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor in postmenopausal breast cancer patients. Clin Camcer Res 1998; 4: 2089–93.

Е.В.Артамонова

РОНЦ им. Н.Н.Блохина РАМН, Москва